Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 February, 2019 02:34 IST
Lupin receives tentative USFDA nod for generic Locoid lotion
Source: IRIS | 12 Feb, 2018, 04.20PM
Comments  |  Post Comment

Pharma major Lupin announced that it has received tentative approval for its Hydrocortisone Butyrate Lotion, 0.1% from the United States Food and Drug Administration (FDA) to market a generic version of Precision Dermatology, Inc.'s Locoid Lotion, 0.1%.

Lupin's Hydrocortisone Butyrate Lotion, 0.1% is the generic equivalent of Precision Dermatology, Inc.'s Locoid Lotion, 0.1%. It is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.

Hydrocortisone Butyrate Lotion, 0.1% had annual sales of approximate USD 16.1 million in the US (IQVIA MAT October 2017).

Shares of the company gained Rs 18.4, or 2.24%, to settle at Rs 839.30. The total volume of shares traded was 124,365 at the BSE (Monday).



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Sector
Aarti Industries signs USD 125 mn multi-year deal - 20-Feb-2019 10:53
Glenmark to present data on Ryaltris at AAAAI 2019 - 20-Feb-2019 10:48
ABB bags train technologies order worth Rs 2.70 bn - 20-Feb-2019 10:30
Cipla, Wellthy Therapeutics announce partnership to offer digital therapeutics - 19-Feb-2019 10:58
Glenmark Pharma receives ANDA approval for Clobetasol propionate foam - 18-Feb-2019 10:45
L&T Construction secures contract for design and construction of major airport - 18-Feb-2019 10:42
Lupin launches Clobazam oral suspension - 15-Feb-2019 16:37
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer